| 000 | 01874 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518023947.0 | ||
| 264 | 0 | _c20201116 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1477-0970 | ||
| 024 | 7 |
_a10.1177/1352458518816612 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCuker, Adam | |
| 245 | 0 | 0 |
_aImmune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. _h[electronic resource] |
| 260 |
_bMultiple sclerosis (Houndmills, Basingstoke, England) _c01 2020 |
||
| 300 |
_a48-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlemtuzumab _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aInterferon beta-1a _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aPurpura, Thrombocytopenic, Idiopathic _xdrug therapy |
| 700 | 1 | _aBass, Ann D | |
| 700 | 1 | _aNadj, Congor | |
| 700 | 1 | _aAgius, Mark A | |
| 700 | 1 | _aSteingo, Brian | |
| 700 | 1 | _aSelmaj, Krzysztof W | |
| 700 | 1 | _aThoits, Timothy | |
| 700 | 1 | _aGuerreiro, Alexandre | |
| 700 | 1 | _aVan Wijmeersch, Bart | |
| 700 | 1 | _aZiemssen, Tjalf | |
| 700 | 1 | _aMeuth, Sven G | |
| 700 | 1 | _aLaGanke, Christopher C | |
| 700 | 1 | _aThangavelu, Karthinathan | |
| 700 | 1 | _aRodriguez, Claudio E | |
| 700 | 1 | _aBaker, Darren P | |
| 700 | 1 | _aMargolin, David H | |
| 700 | 1 | _aJannsens, Ann | |
| 773 | 0 |
_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 26 _gno. 1 _gp. 48-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1352458518816612 _zAvailable from publisher's website |
| 999 |
_c29393442 _d29393442 |
||